Additional Positive Data From Pivotal ASPEN Study of Brensocatib in Patients With Bronchiectasis to Be Presented at the 7th World Bronchiectasis Conference
Additional Positive Data From Pivotal ASPEN Study of Brensocatib in Patients With Bronchiectasis to Be Presented at the 7th World Bronchiectasis Conference
—New Graph Depicting 52-Week FEV1 Data Illustrate Significantly Less Decline in Lung Function for Brensocatib 25 mg Versus Placebo—
新的圖表描繪了52周的FEV1數據，說明Brensocatib 25 mg相對於安慰劑引起的肺功能下降明顯減少。
—Additional Exploratory Endpoints to be Presented, Including FVC and Patient-Reported BEST Score—
還將呈現其他探索性終點，包括FVC和患者報告的BEST評分。
BRIDGEWATER, N.J., July 3, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that additional positive results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis, will be presented tomorrow, July 4, 2024, at the 7th World Bronchiectasis Conference (WBC) in Dundee, Scotland. Slides from this presentation can be found here.
納斯達克全球生物製藥公司Insmed於2024年7月3日表示， ASPEN研究將於2024年7月4日在蘇格蘭鄧迪召開的第7屆世界支氣管擴張症大會上公佈額外的積極結果。該研究是一項全球性的隨機、雙盲、安慰劑對照的Ⅲ期研究，旨在評估brensocatib對非囊性纖維化支氣管擴張症患者的療效、安全性和耐受性。th此次演示的幻燈片可以在此處找到。
譯文內容由第三人軟體翻譯。